Newswise University of Maryland School of Medicine (UMSOM) Professor of Diagnostic Radiology & Nuclear Medicine, Linda Chang, MD, MS, received the National Institute on Drug Abuse (NIDA) 2021 Avant Garde Award (DP1) for HIV/AIDS and Substance Use Disorder Research a National Institutes of Health (NIH) Directors Pioneer Award. This prestigious award supports researchers with exceptional creativity, who propose high-impact research with the potential to be transformative to the field. Her proposed project will involve a team of experts in brain imaging, infectious diseases, addiction, animal research, and gene-editing technology with the goal to essentially eradicate all traces of HIV from the body, and treat commonly co-existing substance use disorders. 2021 Avant Garde Awardees are expected to receive more than $5 million over five years.
I am extremely pleased, and feel very fortunate to have received this award, says Dr. Chang, who has a secondary appointment in the Department of Neurology at UMSOM. This project takes my work in a new direction. I believe my track record of being able to work across multiple disciplines with various researchers to initiate new areas of research and getting good results, along with the outstanding collaborators and resources at UMB, gave the proposal reviewers confidence that my team and I can significantly advance this new project.
About 38 million people around the world live with HIV, according to the Centers for Disease Control and Prevention. Although antiretroviral therapies can treat HIV to the point of undetectable viral levels and lead to long, healthy lifespans, these medications must be taken for life to prevent a resurgence, as HIV can hide from these drugs by integrating copies of itself into a persons genome. Once the drugs are stopped, the virus can reemerge.
From start to finish, Dr. Changs plan is to remove HIV from the genome, even in tough to reach spots like the brain, get more of the antiretroviral therapies into the brain, and stimulate the reward system in the brain to reduce drug cravings. The work will start out in mice before it can be tested in people.
Dr. Chang plans to use the gene-editing technology known as CRISPR to cut out copies of the hidden HIV genes in the genomes of mice, so they can be eradicated by antiretroviral drugs.
However, getting the CRISPR therapy into the brain can be difficult because of the blood-brain barrier, which protects the brain from infectious bacteria and foreign substances. The blood-brain barrier also prevents antiretroviral drugs from reaching high enough concentrations in the brain and central nervous system to effectively destroy HIV.
To seek out HIV in the brain, Dr. Chang and her team will temporarily disrupt the blood-brain barrier to allow more of the antiretroviral drugs or the CRISPR compounds to cross over the blood-brain barrier using an unique resource at the University of Marylandthe MRI-guided focused ultrasound system. This technique uses the MRI scan to help guide 2,000 pinpointed beams of high energy sound waves, along with microscopic bubbles, to non-invasively and temporarily open an area of the brain with the goal of eliminating the hidden reservoirs of virus in the brains immune cells.
About half of the people with HIV use substances, like drugs or alcohol, or have substance use disorders. Even tobacco or cannabis use in people with HIV is at 2-3 times that of the general population. Together with Victor Frenkel, PhD, an Associate Professor in the Department of Radiology and the Director of Translational Focused Ultrasound, and Donna Calu, PhD, Assistant Professor in the Department of Anatomy and Neurobiology, Dr. Chang will use low energy MR-guided focused ultrasound to suppress brain activity in the reward center of the brain, the nucleus accumbens. They hope this approach will suppress drug cravings in people with HIV who have substance use disorders.
The different components of this project will first be tested in mouse or rat models before moving onto clinical studies. As HIV does not normally infect mice, researchers use humanized mice that have weak immune systems, which are replaced with human blood stem cells that become human immune cells that can be infected with HIV. Although these humanized mice make lots of T cells a main cell for HIV infectionthey dont make the immune cells that HIV uses to hide in the brain, known as microglia. Recently, Dr. Changs collaborator Howard E. Gendelman, MD, Margaret R. Larson Professor of Internal Medicine and Infectious Diseases Chair at University of Nebraska Medical Center, and his lab created a modified humanized mouse that has an extra human gene that allows the human blood stem cells to now make microglia.
These new mice mean that these experiments can be done in a fraction of the time and cost and without the other hurdles that come along with using non-human primates, which are the only other animal that a special strain of HIV can infect, says collaborator Alonso Heredia, PhD, Associate Professor of Medicine and scientist at UMSOMs Institute of Human Virology.
He adds, There have been many attempts to eradicate HIV in the body, and it is thought they have not been successful, in part because we cannot get to the HIV reservoirs in the brain. If this works, we will be much closer to a practical cure for HIV. Dr. Heredia will be collaborating with Dr. Chang on this project using HIV-infected humanized mice that he has developed for his other ongoing projects.
For the addiction studies, Dr. Changs team will use the expertise and rodent models of addiction developed and optimized by Mary Kay Lobo, PhD, Professor of Anatomy and Neurobiology, and Dr. Calu. The mice will self-administer fentanyl, a powerful, synthetic opioid.
Dr. Frenkel and Dheeraj Gandhi, MBBS, Professor of Diagnostic Radiology and Nuclear Medicine and Clinical Director of Center of Metabolic Imaging and Therapeutics at UMSOM, are the teams MRI-guided focused ultrasound and clinical research experts.
My hearty congratulations to Dr. Chang and her colleagues and collaborators. If anything is called cutting edge this work surely qualifies for that praise. We wish this group all the success possible, said Robert C. Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine, Co-Founder and Director, Institute of Human Virology (IHV), University of Maryland School of Medicine, a Global Virus Network (GVN) Center of Excellence, and GVN Co-Founder and International Scientific Advisor.
Dr. Chang is an expert in using brain imaging to study how HIV or drug use affect the brain in adults and during adolescence, and how exposure to drugs in the womb affects childhood development. She has also conducted clinical trials for treating HIV-associated cognitive disorders and substance use disorders.
Dr. Chang joined UMSOM in 2017 through the Deans initiative Special Trans-Disciplinary Recruitment Award Program (STRAP). The STRAP Initiative was part of UMSOM's multi-year research strategy ACCEL-Med (Accelerating Innovation and Discovery in Medicine) to increase the quality and reputation of clinical and basic science research bringing UMSOM among other top-tier medical research schools.
Dr. Changs arrival to UMSOM spurred the exact kind of collaborative efforts we had hoped to foster through our recruitment program in order to accelerate discoveries, treatments and cures for the worlds most pressing diseases, says E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, UMSOM.I look forward to following her teams progress on this ambitious project in the hope that one day we can eradicate HIV.
Dr. Chang served on the National Advisory Council on Drug Abuse for NIDA and is a current member on the Council of Councils at the NIH.
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest-growing, top-tier biomedical research enterprises in the world -- with 45 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research.
With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for nearly 2 million patients each year. The School of Medicine has more than $563 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows.
The combined School of Medicine and Medical System (University of Maryland Medicine) has an annual budget of nearly $6 billion and an economic impact of more than $15 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visitmedschool.umaryland.edu
- Hunterian Medicine Licenses Inscriptas MAD7 Nuclease to Advance Gene Editing Research and Development - Yahoo Finance - October 17th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 17th, 2021
- 4 Biotechs to Watch Amid Rising Prominence of Gene Therapies - Yahoo Finance - October 17th, 2021
- The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics - Yahoo Finance - October 17th, 2021
- Could an Old Drug Be a New Alzheimers Treatment? - AARP - October 17th, 2021
- 5 Slides: Gene therapy and the promise for rare disease - State of Reform - State of Reform - October 17th, 2021
- Harvard's R&D alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 17th, 2021
- Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress - StreetInsider.com - October 17th, 2021
- Genetic screening test leads to discovery of a family trait - Sanford Health News - October 17th, 2021
- Filling the gaps: connecting genes to diseases through proteins - EurekAlert - October 17th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - GlobeNewswire - October 17th, 2021
- Polygenic screening of embryos is here, but is it ethical? - The Guardian - October 17th, 2021
- Wolter Earns Young Investigator Award | Newsroom - UNC Health and UNC School of Medicine - October 17th, 2021
- Patient Care on the Precipice of Transformation at Penn Medicine's New Pavilion - pennmedicine.org - October 17th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 11th, 2021
- CRISPR is revolutionizing medicine its origin story is pretty incredible, too - Freethink - October 11th, 2021
- Longevity Foundation to Fund Geroscience Research with 860M - Labiotech.eu - October 11th, 2021
- Explained | The 2021 Nobel Prize in Physiology or Medicine - The Hindu - October 11th, 2021
- Cancer is a Key Focus in Cell and Gene Therapy Research - PR Web - October 11th, 2021
- Nobel prize in medicine won by US scientists who unlocked the secrets of our sense of touch - Livescience.com - October 11th, 2021
- UK Study Suggests Personalized Medicine May be the Future of Alzheimer's Disease Treatment - UKNow - October 11th, 2021
- Family of black woman hailed as 'mother of modern medicine' to sue company for 'stealing her cells' - The Voice Online - October 11th, 2021
- Most expensive medicine in the world soon to be covered in basic health insurance package - NL Times - October 11th, 2021
- Alzheimer's: The heretical and hopeful role of infection - BBC News - October 11th, 2021
- Follow the Money: CRISPR, Next-Gen Neuroscience, Protein Platforms - Bio-IT World - October 11th, 2021
- Diamyd Medical : The diabetes vaccine Diamyd to be featured in two oral presentations at the International Diabetes Federation Congress -... - October 11th, 2021
- NIH awards UT Southwestern researchers $4.4 million to study the genetic basis of vocal learning - UT Southwestern - October 11th, 2021
- Cancer Profiling Market: Rising cancer cases boost the demand for early diagnosis to drive the market - BioSpace - October 11th, 2021
- State-of-the-art manufacturing facility opens in Scottish capital - Scottish Business News - October 11th, 2021
- New Nobelist David Julius was a standout from the start - University of California - October 11th, 2021
- $14.6 million NIH award will accelerate gene therapy research for rare disorder - Wexner Medical Center - The Ohio State University - October 3rd, 2021
- United States Regenerative Medicine Markets to 2026: Focus on Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies, Tissue Engineered... - October 3rd, 2021
- Chardan Analyst: Gene Therapy Stocks Start their Long Ride to the Upside - The Wall Street Transcript - October 3rd, 2021
- UC San Diego Cancer Cell Mapping Research May Improve Chemotherapy - Times of San Diego - October 3rd, 2021
- CATO SMS Appoints Vice President of Regulatory Strategy, Cell and Gene Therapy - PRNewswire - October 3rd, 2021
- How did humans lose their tails? Scientists discover what happened. - Mashable - October 3rd, 2021
- mRNA Could Fight Diseases Such as Alzheimer's and Cancer, With Help of UVA Scientist - University of Virginia - October 3rd, 2021
- Collaboration Aims to Improve GeneType Breast Cancer Test's Utility in African Americans - Clinical OMICs News - October 3rd, 2021
- Grant Awarded to Better Define Gastric Cancer Risks of the Hereditary Diffuse Gastric Cancer Gene CTNNA1 - PRNewswire - October 3rd, 2021
- The Multiple System Atrophy Coalition Announces a Groundbreaking Project to Explore the Genetics of MSA - Johnson City Press (subscription) - October 3rd, 2021
- Protective Biosystems: Parasites to Fight Chemical and Biological Weapons - Global Biodefense - October 3rd, 2021
- Psychiatry on the Brink: Precision Medicine Finally Streamlines Therapeutic Selection - BioSpace - October 3rd, 2021
- DMD Gene Therapy SGT-001 Improves Lung Function in Boys in Trial - Muscular Dystrophy News - October 3rd, 2021
- OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy - Yahoo Finance - October 3rd, 2021
- Scientists discover 14 genes that cause obesity - EurekAlert - October 3rd, 2021
- UNC Awarded $24-million NIH Grant to Improve Genomic, Precision Medicine | Newsroom - UNC Health and UNC School of Medicine - September 24th, 2021
- UNC lands $24M grant to drive more genetic research for precision medicine - WRAL Tech Wire - September 24th, 2021
- The Blueprints of Health - Scientific American - September 24th, 2021
- Rare gene mutations lead to greatly increased risk of fatal chemotherapy toxicity - EurekAlert - September 24th, 2021
- DiNAQOR Appoints Medical Device Leader Mark Dehdashtian to Oversee New U.S.-Based Division, Device Development and Production - Yahoo Finance - September 24th, 2021
- Sio Gene Therapies to Participate in Upcoming Conferences - GlobeNewswire - September 24th, 2021
- Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss | More News | News... - September 24th, 2021
- Backed by Penn Medicine Research, National Task Force Recommends Removing Race from Kidney Function Equation - pennmedicine.org - September 24th, 2021
- Protein Pair Promote Vascularization of Breast and Liver Tumors: Suggest Potential Therapeutic Targets - Genetic Engineering & Biotechnology News - September 24th, 2021
- Novel biomarkers of sepsis occurrence and progression | IJGM - Dove Medical Press - September 24th, 2021
- Michael S. Cartwright, MD, MS Awarded the Jun Kimura Outstanding Educator Award From AANEM - Newswise - September 24th, 2021
- Discovery of Obesity-Causing Genes Could Lead to Drugs to Prevent Weight Gain - University of Virginia - September 24th, 2021
- Vertex's Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with... - September 24th, 2021
- STEAMM Rising Initiative announced to better prepare Columbus City students for careers - The Columbus Dispatch - September 24th, 2021
- Abingworth, Gimv and Pfizer back stealthy Swiss startup's $61M round to crack gene therapy delivery - FierceBiotech - September 17th, 2021
- Albert Einstein College of Medicine awarded $5 million for research on intellectual and developmental disabilities - EurekAlert - September 17th, 2021
- ONLINE: When Gene Therapy Meets Reality - Isthmus - September 17th, 2021
- AGC boost pDNA and mRNA capacity with expansion - BioProcess Insider - BioProcess Insider - September 17th, 2021
- Vaccines in your salad? Scientists growing medicine-filled plants to replace injections - Study Finds - September 17th, 2021
- How to beat cancer? Find the genes that help it hide - Scope - September 17th, 2021
- Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance for Public Reimbursement of CFTR Modulators Extended to Include... - September 17th, 2021
- Baylor College of Medicine Developed a Novel Approach to Select Subjects for Gene Experiments More Convenient and Faster than Fruit Fly Screening... - September 16th, 2021
- 5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal - Yahoo Finance - September 16th, 2021
- Albert Einstein College of Medicine Awarded $5 Million for Research on Intellectual and Developmental Disabilities - PRNewswire - September 16th, 2021
- Pioneering Gene Therapy Freed Her of Sickle Cell. Is a Cure at Hand? - The New York Times - September 16th, 2021
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2021: Focus on Drug Discovery & Toxicity Studies, Academic Research, Cell & Gene... - September 16th, 2021
- Sarepta Therapeutics to Showcase Data from its Gene Therapy - GlobeNewswire - September 16th, 2021
- SNP of the SREK1 gene is associated with COPD in Kashi | COPD - Dove Medical Press - September 16th, 2021
- University of Saskatchewan to Advance Ovarian Cancer Tumor Bank, Genetic Test With Government Grant - Precision Oncology News - September 16th, 2021
- Convergence: Regulatory considerations in advancing gene and cellular therapies - Regulatory Focus - September 16th, 2021
- Cracking the code - The West Australian - September 16th, 2021
- American Gene Technologies Appoints Dr. Robert R. Redfield as Special Advisor to the CEO - PR Web - September 16th, 2021
- Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary... - September 16th, 2021
- Genetic meds pioneer James Wilson has a new startup, this time in gene editing - MedCity News - September 12th, 2021
- Lung cancer patients in England to receive Amgen drug that targets a gene mutation - Reuters - September 12th, 2021